Evidence map›Paper›PMID 38965822›Full record

Trial reportExperimental physiology2024

Growth differentiation factor 15 is not modified after weight loss induced by liraglutide in South Asians and Europids with type 2 diabetes mellitus.

Carlijn A Hoekx, Maaike E Straat, Maurice B Bizino, Huub J van Eyk, Hildebrandus J Lamb, Johannes W A Smit, Ingrid M Jazet, Saskia C A de Jager, Mariëtte R Boon, Borja Martinez-Tellez

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Experimental physiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Trial
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Carlijn A HoekxDivision of Endocrinology, Department of Medicine, Leiden University Medical Center, Leiden, The Netherlands.ORCID https://orcid.org/0000-0001-6941-7339
Maaike E StraatDivision of Endocrinology, Department of Medicine, Leiden University Medical Center, Leiden, The Netherlands.
Maurice B BizinoDivision of Endocrinology, Department of Medicine, Leiden University Medical Center, Leiden, The Netherlands.
Huub J van EykDivision of Endocrinology, Department of Medicine, Leiden University Medical Center, Leiden, The Netherlands.
Hildebrandus J LambDepartment of Radiology, Leiden University Medical Center, Leiden, The Netherlands.
Johannes W A SmitDepartment of Medicine, Radboud University Medical Center, Nijmegen, The Netherlands.
Ingrid M JazetDivision of Endocrinology, Department of Medicine, Leiden University Medical Center, Leiden, The Netherlands.
Saskia C A de JagerLaboratory of Translational Immunology, University Medical Centre Utrecht, Utrecht, The Netherlands.
Mariëtte R BoonDivision of Endocrinology, Department of Medicine, Leiden University Medical Center, Leiden, The Netherlands.
Borja Martinez-TellezDivision of Endocrinology, Department of Medicine, Leiden University Medical Center, Leiden, The Netherlands.

Funding

Dutch Research Council NWO 09150161910073Ministerio de Universidades y la Unión Europea-NextGenerationEU RR_C_2021_04
6 · The paper itself

Abstract

Glucagon-like peptide-1 receptor (GLP-1R) agonists induce weight loss in patients with type 2 diabetes mellitus (T2DM), but the underlying mechanism is unclear. Recently, the mechanism by which metformin induces weight loss could be explained by an increase in growth differentiation factor 15 (GDF15), which suppresses appetite. Therefore, we aimed to investigate whether the GLP-1R agonist liraglutide modifies plasma GDF15 levels in patients with T2DM. GDF15 levels were measured in plasma samples obtained from Dutch Europids and Dutch South Asians with T2DM before and after 26 weeks of treatment with daily liraglutide (n = 44) or placebo (n = 50) added to standard care. At baseline, circulating GDF15 levels did not differ between South Asians and Europids with T2DM. Treatment with liraglutide, compared to placebo, decreased body weight, but did not modify plasma GDF15 levels in all patients, or when data were split by ethnicity. Also, the change in plasma GDF15 levels after treatment with liraglutide did not correlate with changes in body weight or HbA

Indexed as

Diabetes Mellitus, Type 2Growth Differentiation Factor 15Hypoglycemic AgentsLiraglutideMetforminWeight LossAgedFemaleGlucagon-Like Peptide-1 ReceptorGlucagon-Like Peptide-1 Receptor AgonistsHumansMaleMiddle AgedSouth Asian PeopleWhite PeopleGDF15 protein, humanGlucagon-Like Peptide-1 ReceptorGlucagon-Like Peptide-1 Receptor AgonistsGrowth Differentiation Factor 15Hypoglycemic AgentsLiraglutideMetforminethnic differencesmetabolic diseasesobesityweight‐reducing drugs

Identifiers

PMID38965822
PMCPMC11291866

What Socratic holds

Texttitle and abstract
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.